Optimal therapy consists of complete resection, which is associated with long-term disease control in more than 95% of patients. 10 Patients in whom the entire tumor is unresectable have a greater chance of disease progression. With STR, adjuvant or salvage radiation treatment is considered 1, 6, 7, 9, 10, [12] [13] [14] [15] [16] [17] but remains controversial; some report a recurrence rate without adjuvant radiation therapy to be only 15%. 10 Others have discussed possible malignant degeneration after radiation treatment. 13, 17 Given that the progression of low-grade gangliogliomas (Grades I and II) is rare, the benefit of using any adjuvant therapy after STR remains unclear. The objective of this study is to examine and review the Mayo Clinic experience of 88 patients with gangliogliomas, their longterm follow-up and risk of recurrence, and the role of radiation therapy after STR or biopsy alone.
Methods

Study Population
This study was approved by the Mayo Clinic Institutional Review Board. The Mayo Clinic tumor registry was queried for data on patients with low-grade ganglioglioma (Grades I and II) who presented between 1970 and 2007. To be included, biopsy confirmation and review of pathology by the Mayo Clinic Department of Pathology was required. Data were retrieved concerning patient presentation, extent of resection, histological grade, adjuvant therapy, and other pertinent prognostic factors, as well as type of recurrence, PFS, and overall survival. This retrospective review is of the 88 patients who met these criteria.
Data Collection
No attempt was made to define an epicenter if multiple sites of brain were involved; rather, all involved sites were recorded. The extent of resection was assessed by the operative report, neurosurgeon's impression, and postoperative imaging when available. A surgical procedure was designated as radical STR when the operative report described "radical subtotal resection," when GTR was clearly the goal of the operation but minimal known tumor was left in situ, or when imaging reports indicated small, questionable amounts of residual tumor after GTR. Radiological images for patients who had neuroimaging data available were obtained from archives. These images underwent a second review and further analysis. All patients were classified by histological type and grade according to WHO criteria. 9, 14, 15 Recurrence information was collected using all available data in the medical record. Specifically, imaging, clinical signs and symptoms, pathology information, or initiation of any additional intervention such as surgery, radiation therapy, or chemotherapy were used to declare progression.
Statistical Analysis
Thirteen possible prognostic factors were analyzed for potential association with both overall survival and PFS outcomes by univariate analysis. These variablesage, sex, tumor size, histology, extent of resection, radiation therapy, chemotherapy, sensory motor symptoms at presentation, supratentorial location, and enhancement on CT and/or MRI-were chosen because of their documented prognostic value. Progression-free survival and overall survival curves were calculated using the KaplanMeier method 6 and compared with the log-rank test. 12 Deaths without documented recurrence were considered as censored observations for recurrence at time of death. All tests were 2-tailed. A p value < 0.05 was considered statistically significant.
Results
Patient, Tumor, and Treatment Characteristics
Patient and tumor factors are outlined in Table 1 . Tumor characteristics were identified from both the operative and radiography reports (CT, MRI, angiography). The starting point of the study interval predated the modern neuroimaging era, but CT data reports were available for 40 patients (46%) and MRI data reports were available for 68 patients (77%). The vast majority of patients (89%) had supratentorial tumors, most commonly within the temporal lobe (n = 38, 43%) as described in imaging and/or operative notes.
Neuroimaging
Of the 88 patients, initial imaging was obtained prior to 1998 in 53 (60%), and thus images were no longer available for review because images obtained prior to 1998 had been purged from the records. Of the 35 patients with diagnoses since 1998, 4 (11%) had no images available for review because the imaging was performed at an outside institution and returned. Another 4 patients only had postoperative imaging available for review, for the same reason. Of the remaining 27 patients for whom preoperative imaging was available for review, 6 (22%) underwent a CT scan and 26 (96%) underwent preoperative MRI. Since 1998, 1 patient had only a postoperative MR image, with preoperative images obtained elsewhere and returned.
Of the 6 patients with a preoperative CT scan, 5 (83%) demonstrated calcification. Of the 26 with preoperative MRI, all demonstrated T1 isointensity and T2 and FLAIR hyperintensity. Diffusion-weighted imaging was not obtained in most cases because the studies were performed for evaluation of seizures or for preoperative planning, and diffusion was not a standard sequence in the protocol for either evaluation. Of the 27 patients, 3 (11%) did not receive intravenous contrast administration and thus contrast enhancement characteristics could not be determined. Of the remaining 24 patients who received intravenous contrast administration, 3 (13%) demonstrated no contrast enhancement, whereas the remaining 21 patients (88%) demonstrated some degree of contrast enhancement. In 19 (90%) of these 21 patients the enhancement pattern was nodular and peripheral, whereas in the remaining 2 patients the enhancement was relatively homogenous throughout the mass. In 22 (81%) of 27 patients, some degree of cystic change was present. Of these 27 tumors, 16 (59%) were located in a temporal lobe. The remaining 11 were scattered, including 2 each (7%) in the frontal lobe, parietal lobe, cerebellum, and midbrain, as well as 1 each (4%) in the occipital lobe, pineal region, and corpus callosum. A typical appearance and location of a cerebral ganglioglioma is shown in Fig.  1 . However, these tumors can occur anywhere, as illustrated in Fig. 2 .
Of the 27 patients with imaging, 24 (89%) underwent resection at our institution. Two patients (7%) underwent biopsy only, and 1 (4%) underwent resection elsewhere. Of the 24 who underwent resection at our institution, 3 operations (13%) were reported as subtotal by the operating surgeon; in the remaining 21 patients (88%), resection was reported as a GTR. Of these 21 tumors, 12 (57%) demonstrated no evidence of residual disease on postoperative MRI; 4 (19%) received no documented imaging follow-up at our institution; in 2 cases (10%), MRI was indeterminate for postoperative change versus residual tumor; and in 3 (14%) of the cases reported as GTR, postoperative imaging demonstrated residual tumor.
Surgery and Recurrence or Progression
Of 84 patients with surgical data, GTR was achieved in 55 patients (65%), STR in 22 patients (26%), and biopsy only in 7 patients (8%). Of the 55 patients who underwent GTR, 9 (16%) experienced recurrence, whereas 15 (68%) of 22 experienced tumor progression after STR and all of these patients underwent biopsy (p < 0.0001, chi-square test). Tumor location was the most frequent reason that patients underwent biopsy rather than undergoing GTR or STR.
Survival Outcomes
The median potential follow-up as of June 2008 was 11.8 years (range 9 months to 34.6 years). The 15-year overall survival rate was 94%. Two patients were known to have died of or with disease, 2 died without known evidence of disease, and 29 patients were alive without evidence of disease at last follow-up. Twenty-one patients were alive with unknown disease status.
Recurrence/Progression Outcomes
Recurrences were documented in 34 patients with a median time to progression of 5.6 years. The 2-, 5-, and 10-year PFS rates were 72%, 58%, and 37%, respectively (Fig. 3, upper) . Extent of resection was found to be strongly associated with PFS (p < 0.0001; Table 2 ; Fig. 3,  lower) . The median time to progression after GTR was 16.7 years, compared with 1.8 years after STR or biopsy. 
Adjuvant/Salvage Radiation Therapy and Chemotherapy
Twenty-four patients were either lost to follow-up or were followed by practitioners outside the Mayo system without any subsequent follow-up information. Adjuvant radiation therapy was given to 1 patient, who received 50.4 Gy in 28 fractions. No patient received a combination of radiation therapy and chemotherapy in the immediate postoperative period. Of the 31 patients who had documented recurrence, 20 (65%) were observed and received no salvage therapy. Of the 7 patients who received radiation therapy for treatment of recurrence (Table 3) , 2 also received chemotherapy. Whole-brain radiation therapy was administered to 1 patient in the 1980s with a total radiation dose of 60 Gy. Two patients who underwent biopsy alone were treated with conformal brain fields to a dose of 50.4 Gy in 28 fractions. One patient was treated with a total radiation dose of 50 Gy to the spinal cord. Adjuvant/salvage radiation therapy was not associated with PFS outcome (p = 0.74; Table 2 ) for the group as a whole. Although the number of patients treated is very small, radiation therapy appeared to improve PFS in patients who were unable to undergo aggressive resection, although the results were not significant. In the 7 patients who received radiation therapy, the median PFS for adjuvant/salvage radiation therapy was 5.6 years vs 1.1 years for no radiation therapy (p = 0.23).
For example, in the 3 patients treated with radiation therapy in the modern era (50.4 Gy to focal fields), 2 of the 3 are alive without progression after radiation therapy. One patient (Case 4) with a cerebellopontine angle tumor was diagnosed at age 11 with a 1-year history of progressive headaches and symptoms of increased intracranial pressure. Subtotal resection was performed due to encasement of cranial nerves IV-VIII, and no clear margin between tumor and cerebellum and brainstem. Imaging revealed progressive growth and return of headaches 6 months after surgery. The patient received radiation therapy and is alive without evidence of progression 3.5 years after radiation therapy.
A second patient (Case 6) was initially observed after a biopsy procedure at age 5 confirmed a tumor in the midbrain and thalamus; 2.9 years later the patient experienced symptomatic and radiographic progression and received radiation therapy. At last follow-up 6 years after radiation therapy, the patient was alive without tumor progression.
In a third patient (Case 7), biopsy alone at age 14 was initially performed for a tumor in the cervicomedullary region. The patient was observed for 4 years until radiographic and symptomatic progression occured. The patient then underwent STR of the tumor, after which pathological analysis again confirmed a ganglioglioma. Symptomatic and radiographic progression was noted 3 years later. The patient then received radiation therapy and experienced improvement in balance difficulties and oscillopsia. One year after radiation therapy, carboplatin and vincristine were initiated for tumor progression noted on radiography. Chemotherapy was poorly tolerated and the patient discontinued after 4 cycles and was transitioned to supportive care. In spite of stable radiographic findings, the patient experienced further neurological decline, and 3 years later she underwent cervical laminectomy at an outside facility. Neurological decline continued over the ensuing 8 years. At last follow-up the patient is living but quadriplegic, dependent on a percutaneous endoscopic gastronomy tube, and requires bilevel positive airway pressure for sleep apnea with no clear radiographic progression. In this series, there were no documented transformations to higher WHO grade in any of the patients.
Discussion
This study involves a review of 88 patients with a diagnosis of WHO Grade I or II ganglioglioma presenting to the Mayo Clinic between 1970 and 2007, with a median follow-up of 11.8 years. Through long-term follow-up . 3 . Progression-free survival curve for the total group of 88 patients (upper) and according to extent of resection (lower).
and in a large patient cohort, our study confirms the excellent prognosis of these patients. This population of patients demonstrates that these tumors are most commonly found in the temporal lobe, and, in agreement with others, we document that the extent of resection is strongly associated with improved PFS outcomes. 18 In regard to neuroradiology for those patients with imaging available for review, the characteristics aforementioned conform to those of gangliogliomas in the literature. Gangliogliomas are classically described as partially cystic, enhancing, cortically based masses, but can occur anywhere, with calcification a common characteristic. 4, 11, 19 Additionally, further retrospective radiological review demonstrated a discrepancy between the operative report of the extent of resection and the radiographic description of resection on postoperative imaging. In addition to providing a discussion on the natural history of this infrequently described lesion, our goal was to ascertain whether a clear recommendation for radiation therapy after resection could be made. While gangliogliomas generally have a favorable prognosis, some may recur and/or progress to anaplasia. This study is notable for the substantial recurrence rate and short time to recurrence for patients who were unable to undergo GTR. Unlike other WHO Grade I tumors such as juvenile pilocytic astrocytoma (Fig. 4) , median time to recurrence for patients who were unable to undergo a GTR was very short (only 1.1 years). Adjuvant radiation treatment- which in our study also included 1 patient who received whole-brain radiation that would not be considered at the present time-delayed time to recurrence to 5.6 years, but the difference was not statistically significant.
The small number of patients precludes any clear conclusions regarding adjuvant therapy from this study. In addition, 24 patients were either lost to follow-up or were followed by practitioners outside the Mayo Clinic system without any meaningful follow-up information. However, these results suggest that a subset of gangliogliomas, those that are either unresectable or multiply recurrent, have a natural history that may be more similar to WHO Grade II low-grade gliomas. Radiation therapy may delay time to progression in this subset of gangliogliomas, as it does in WHO Grade II gliomas.
Until further histopathological or genetic classification is available, this large, retrospective series confirms the importance of GTR in reducing risk of recurrence and improving survival. Radiation therapy may delay the time to progression for unresectable tumors.
Conclusions
This study reviewed 88 patients with a diagnosis of WHO Grade I or II ganglioglioma with a median followup of 11.8 years. Our study confirms, through long-term follow-up and a large patient cohort, the excellent prognosis of these patients. We document that the extent of resection is strongly associated with improved PFS outcomes. 18 Our study also confirms the substantial recurrence rate and short time to recurrence for patients who are unable to undergo GTR. Unlike other WHO Grade I tumors, median time to recurrence for patients who were unable to undergo GTR was 1.1 years. Adjuvant radiation delayed time to recurrence to 5.6 years, but the difference was not statistically significant, likely due to the small numbers of patients who received radiation therapy after resection. However, these results do suggest that a subset of gangliogliomas, those that are either unresectable or multiply recurrent, have a natural history more similar to WHO Grade II low-grade gliomas. As in WHO Grade II gliomas, radiation therapy may delay time to progression in this subset.
